-
SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors (opens in a new tab)
SAB also announces closing of $7.5 million financing, the first tranche of $130 million private placement SIOUX FALLS, S.D., Oct. 05, 2023 (GLOBE…
-
SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes (opens in a new tab)
Funding to support clinical advancement of SAB-142, a potential disease-modifying treatment Financing led by RA Capital Management, with participation…
-
SAB Biotherapeutics Provides Company Update for Q2 2023 Financial Results (opens in a new tab)
SIOUX FALLS, S.D., Aug. 21, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics ( Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel…
-
SAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes at FOCIS 2023 (opens in a new tab)
SAB highlights results from GLP toxicology study confirming SAB-142's mechanism of action at the 23rd Federation of Clinical Immunology Societies (FOCIS)…
-
SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International Convention (opens in a new tab)
SAB Biotherapeutics President & Chief Executive Officer Eddie Sullivan, Ph.D. to present novel DiversitAb™ platform pipeline, with emphasis on partnering…
-
SAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update: Breakthrough Immunotherapy Innovations (opens in a new tab)
SIOUX FALLS, S.D., May 19, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ: SABS ), a clinical-stage biopharmaceutical company with a novel…
-
SAB Biotherapeutics Provides Company Update for Q1 2023 Financial Results (opens in a new tab)
SIOUX FALLS, S.D., May 16, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics ( Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel…
-
SAB Biotherapeutics Announces First Publication of Promising Nonclinical Data for SAB-183 Against Pneumonic Plague in the Journal Antibodies (opens in a new tab)
In study conducted for U.S. Army Medical Research Institute, SAB-183 demonstrated strong immune protection and response against Yersinia pestis…
-
SAB Biotherapeutics Announces Progress on U.S. FDA’s Phased Review of Company’s Groundbreaking DiversitAb™ Platform (opens in a new tab)
- FDA has approved five of seven sections in a rolling submission required for a New Animal Drug Application (NADA) for Company’s antibody generating…
-
SAB Biotherapeutics Presents Positive Phase 1 and 2a Data for SAB-176 Influenza Immunotherapy at ISIRV-AVG Conference (opens in a new tab)
First fully-human multi-epitope binding broadly neutralizing immunoglobulin antibody therapeutic being developed for treatment of high-risk patients…